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Abstract
Background: Shared decision-making (SDM) is considered a key component of high quality cancer care and may
be supported by patient decision aids (PtDAs). Many patients, however, face multiple social disadvantages that may
influence their ability to fully participate in SDM or to use PtDAs; additionally, these social disadvantages are among
the determinants of health associated with greater cancer risk, unwarranted variations in care and worse outcomes.
The purpose of this systematic review is to describe the extent to which disadvantaged social groups in the United
States (US) have been included in trials of cancer-related PtDAs and to highlight strategies, lessons learned and
future opportunities for developing and evaluating PtDAs that are appropriate for disadvantaged populations.
Methods: We selected cancer-related US studies from the Cochrane 2014 review of PtDAs and added RCTs
meeting Cochrane criteria from searches of PubMed, CINAHL, PsycINFO (January 2010 to December 2013); and
reference lists. Two reviewers independently screened titles/abstracts; three reviewers independently screened full
text articles, performed data extraction and assessed: 1) inclusion of participants based on seven indicators of social
disadvantage (limited education; female gender; uninsured or Medicaid status; non-U.S. nativity; non-White race or
Hispanic ethnicity; limited English proficiency; low-literacy), and 2) attention to social disadvantage in the
development or evaluation of PtDAs.
Results: Twenty-three of 39 eligible RCTs included participants from at least one disadvantaged subgroup, most
frequently racial/ethnic minorities or individuals with limited education and/or low-literacy. Seventeen studies
discussed strategies and lessons learned in attending to the needs of disadvantaged social groups in PtDA
development; 14 studies targeted disadvantaged groups or addressed subgroup differences in PtDA evaluation.
Conclusions: The diversity of the US population is represented in a majority of cancer-related PtDA RCTs, but fewer
studies have tailored PtDAs to address the multiple social disadvantages that may impact patients’ participation in
SDM. More detailed attention to the comprehensive range of social factors that determine cancer risk, variations in
care and outcomes is needed in the development and evaluation of PtDAs for disadvantaged populations.
Trial registration: Registered 24 October 2014 in PROSPERO International prospective register of systematic
reviews (CRD42014014470).
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Background
The social determinants of health (SDH) are conditions in
which people live, learn, work and play that interact with
individual-level characteristics (e.g., age, gender, genetics,
behavior) to affect a wide range of health risks and out-
comes [1–3]. In the cancer care continuum, rates of inci-
dence and death for the most common cancer types vary
considerably within and across socioeconomic groups [4].
However, patients in the United States (US) who are
members of certain disadvantaged subgroups (e.g., racial/
ethnic minorities, the uninsured or underinsured and indi-
viduals with limited education, low income or unhealthy
living conditions) are more likely than those in advantaged
groups to be diagnosed with cancer at later stages [4–9],
undergo greater variation in screenings and treatments re-
ceived [4, 5, 8–11], and experience higher rates of morbid-
ity and mortality [4, 5, 8, 9, 12, 13]. Compared to those in
advantaged groups, cancer patients in disadvantaged sub-
groups are also more likely to report worse patient-
provider communication and quality of care [14].
In recent years, the call to address SDH as key drivers
of health inequities has gained momentum among health
system leaders and policymakers in the US. Objectives
outlined in Healthy People 2020 emphasize the import-
ance of addressing SDH as one of four overarching goals
for the decade [2]. New research also identifies the need
to move beyond simply recognizing the fundamental
role upstream SDH play in influencing health toward
using this knowledge to develop and evaluate interven-
tions that examine the mechanisms through which SDH
influence downstream processes of care and outcomes
[1, 15–18]. Interventions involving patient decision aids
(PtDAs), developed with attention to SDH, represent im-
portant opportunities to influence patient-provider com-
munication and shared decision making (SDM) processes.
PtDAs are tools (e.g., brochures, videos, internet-based
programs) designed to help individuals participate in de-
cisions about their healthcare by preparing them to dis-
cuss and make informed, values-based decisions in
partnership with their providers [19–21]. The Institute
of Medicine (IOM) has highlighted the need to support
engagement in SDM, using PtDAs when available, as in-
tegral to delivering high quality cancer care [22]. In
order to accomplish this goal, PtDAs must be appropri-
ate for their intended audiences and present factual, bal-
anced information in easy-to-understand formats that
help patients consider the pros and cons of the options
available to them. Consensus-based standards offer guid-
ance on what should be included in the PtDAs and how
the tools should be developed, including detailed in-
structions about using plain language to support the
needs of people with limited reading skills [23, 24].
The standards, however, are largely silent about ad-
dressing the needs of people who face other social
disadvantages that may influence health care decision
making [1, 25, 26].
The multiple causal pathways through which social
factors are theorized to shape health are long and com-
plex [1, 17, 18, 27, 28]. We posit that SDH may influence
patient-provider interactions and SDM by limiting the
actual and/or perceived options available to patients. For
example, limited education, literacy or English proficiency
(LEP) may obstruct patient-provider communication, even
when translators are available, or limit patients’ perceived
ability to act on the information they receive [29–31]. Eco-
nomic instability (e.g., low income, hourly employment,
transient housing) may cause patients to delay or forego
needed care because they are unable to afford co-pays/
cost-shares, to purchase or appropriately store prescribed
therapies, or to take time away from work for longer-term
treatments [1, 17]. It may also limit one’s ability or willing-
ness to use interventions, such as PtDAs, that require reli-
able computer and/or high speed internet access [32, 33].
Limitations of the built environment (e.g. inadequate ac-
cess to healthy foods, transportation, safe parks) may
cause patients not to choose treatment options that re-
quire lifestyle and behavior changes or travel to certain
areas for treatment [1, 17]. Lack of family/social support
may render home- and/or community-based treatments
less desirable, while social norms/attitudes (e.g., perceived
and/or actual discrimination) may lead patients and their
families to distrust the advice of their providers or health
system officials [1, 17, 34, 35]. Most certainly, access to
healthcare (e.g., access to providers, insurance status) may
reduce patients’ actual or perceived access to certain pro-
viders/facilities and/or specific treatments not covered by
their insurance plans [2, 25, 27, 34]. In other words, when
presented with more than one option, patients may not
perceive that the full range of options is available to them
based on their personal circumstances. We argue that
PtDAs for disadvantaged patients should be tailored to ad-
dress SDH because such tools can then help them think
through and, importantly, share with their clinicians con-
cerns about how SDH-related barriers influence their
preferences for treatment.
Despite the increasing number of PtDAs being devel-
oped, little is known about the availability of cancer-
related PtDAs evaluated in the US that address the
pathways through which SDH may influence the decision
making processes of disadvantaged patients. The purpose
of this review is to address this gap in the literature. We
specifically aim to answer the questions: 1) To what extent
have disadvantaged social groups been included in ran-
domized controlled trials (RCTs) of cancer-related PtDAs
conducted in the US; and 2) What are the strategies and
lessons learned about developing and evaluating PtDAs
that address one or more SDH or otherwise support the
decision making needs of disadvantaged audiences?
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Methods
Eligibility criteria, search methods, study selection and
data extraction
We examined all RCTs of PtDAs that were found in the
2014 updated Cochrane systematic review of patient de-
cision aids [20] plus 6 other trials identified in an inde-
pendent search of PubMed, CINAHL and PsycINFO
(January 2010 through December 2013) using terms
similar to the Cochrane protocol (Additional file 1). We
included studies that met the Cochrane criteria; that is,
they used a RCT design and evaluated a PtDA as part of
the intervention. We eliminated duplicate studies and
excluded studies that were not conducted in the US, did
not target cancer-related decisions, or did not focus on
active decision making. We focus our review on the US
because there are major differences between the US and
other high income countries in the way healthcare is fi-
nanced and delivered that may impact patient-provider
interactions and SDM processes. These differences are
particularly relevant when examining socially disadvan-
taged patients. Neither study quality nor the neutrality
of the PtDA was considered in judging eligibility for in-
clusion; those assessments are available elsewhere for
studies included in the Cochrane review [20]. Reference
lists from the RCTs were also searched (and references
of those references, if necessary) to identify related articles
reporting quantitative and/or qualitative information rele-
vant to development of the PtDAs. Two authors (KRE,
GRK) independently reviewed article titles/abstracts to
assess eligibility based on our inclusion/exclusion cri-
teria. Three authors (KRE, GRK, NMD) independently
reviewed the full text of potentially eligible articles
and extracted specified data using an electronic form,
and disagreements were resolved by consensus; KRE
aggregated the results. When available, multiple re-
ports from the same study were reviewed for relevant
data but counted as a single study.
Measures
Inclusion of disadvantaged subgroups in RCTs
We evaluated inclusion of disadvantaged subgroups in
the selected RCTs based on documentation of seven sam-
ple characteristics related to social disadvantage: limited
education; female gender; uninsured or Medicaid status;
non-US nativity; non-White race or Hispanic ethnicity;
limited English proficiency (LEP); and low-literacy. These
population characteristics are associated with inequities in
healthcare access and, because they are recommended in
reporting guidelines for systematic reviews focused on
health equity [36], they were expected to be readily avail-
able in published studies. For disadvantaged subgroups
other than those with LEP or low-literacy, we classified
studies as inclusive when a proportion of the sample
met or exceeded US national averages for the specified
subgroup [37, 38]. Studies in which individuals with LEP
were eligible to participate and studies that targeted low-
literacy populations were also considered inclusive. Sub-
group definitions for each criterion are given here:
1. Limited Education: ≥ 13 % less than high school
(HS), ≥ 30 % HS or general educational development
(GED) certificate, cumulatively, ≥ 43 % HS or less;
2. Female Gender: ≥ 50 % female, unless gender-
specific condition;
3. Uninsured or Medicaid Status: ≥ 16 % uninsured, ≥
16 % Medicaid beneficiaries or, cumulatively, ≥ 32 %
uninsured or Medicaid beneficiaries;
4. Non-US Nativity: ≥ 12 % born outside the US;
5. Non-White Race or Hispanic Ethnicity: ≥ 13 %
Black, ≥ 16 % Hispanic, ≥ 5 % Asian/Native
Hawaiian or Pacific Islander (Asian/NHPI) or < 63 %
non-Hispanic White;
6. LEP: study facilitated participation using ≥ 1
language other than English;
7. Low-Literacy: study measured and reported
participants’ literacy or health literacy as low, or
described participants as being from low-literacy
populations.
We coded studies as “Yes” (met a criterion), “No” (did
not meet a criterion or did not report data related to a
criterion) or “Not Applicable” (criterion was not applic-
able to the cancer context; e.g., breast cancer studies
limited to female patients; prostate cancer studies lim-
ited to male patients).
Attention to SDH in PtDA development
To address this aim, we examined the included RCTs and
related articles that we were able to identify through cited
and citing references for documentation of a systematic
process that explicitly investigated the needs of one or
more disadvantaged subgroups in the development of the
PtDA. We distinguish this from the previous measure (in-
clusion) because an RCT may have included disadvantaged
groups in the samples but provided no evidence of atten-
tion to social disadvantage in how the aid was developed.
We also reviewed sources for study context; eligibility cri-
teria; identification of a conceptual framework; descriptions
of the PtDA format; intended delivery mode/setting/tim-
ing; subgroups targeted in the development process; and
development strategies used to inform PtDA content and
to test the usability/feasibility of the intervention. We de-
fined usability/feasibility testing as activities intended to
assess participants’ ability to understand and complete
intervention-related tasks; time required to complete such
tasks; satisfaction with (acceptability) and estimated or ac-
tual use of the intervention (demand); and other activities
related to the assessment of intervention feasibility [37].
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Attention to SDH in PtDA evaluation
We examined articles for any discussion of the effective-
ness of the PtDA in a disadvantaged subgroup based on:
1) the authors’ stated a priori objectives to evaluate the
effectiveness of the PtDA in the targeted subgroup(s), 2)
use of evaluation tools specifically designed for disadvan-
taged subgroups (e.g., low-literacy version of a validated
questionnaire), or 3) stratified subanalyses and/or PtDA-
by-subgroup interactions. Here, we distinguish attention
to SDH in PtDA evaluation from our measure of inclu-
sion because studies may have failed to meet our criteria
for including socially disadvantaged groups in the sam-
ple but still considered social disadvantage in the ana-
lytic plan. In contrast, studies may have met our criteria
for including disadvantaged groups in the samples but
failed to consider subgroup differences in the analytic
plan. In the latter case, inferences about disadvantaged
groups cannot be made.
Results
Characteristics of the RCTs
The initial literature search returned 223 unique refer-
ences; 106 were selected for full-text review (Fig. 1). Of
these references, 39 RCTs of PtDAs reported in 46 articles
[38–83] published between 1995 and 2013 met our inclu-
sion criteria (Table 1). The RCTs addressed three cancers:
breast (BCa, k = 12), colorectal (CRC, k = 7) and prostate
(PCa, k = 20); and primarily supported screening or pre-
vention decisions (k = 32). The BCa studies focused on
genetic testing/counseling (k = 5), high risk prevention
(k = 3), reconstruction surgery (k = 1), and breast con-
serving therapy (BCT) versus mastectomy (k = 3). Six
CRC studies addressed screening (fecal occult blood test-
ing, flexible sigmoidoscopy, colonoscopy, double contrast
barium enema); one addressed microsatellite instability
(MSI) genetic testing. Seventeen studies evaluated PtDAs
designed to support PCa screening decisions (prostate
specific antigen testing or digital rectal exam); and three
studies addressed PCa treatment (active surveillance,
prostatectomy, radiation therapy or medication). Nearly
all studies were conducted in urban/suburban areas; only
two studies were conducted in rural areas. Regional vari-
ation was relatively evenly distributed.
Inclusion of disadvantaged subgroups
Twenty-three of 39 studies met one or more of our a
priori criteria for inclusion of disadvantaged subgroups:
HS or less education (k = 12); females (6-of-7 CRC screen-
ing studies); Medicaid or uninsured status (k = 7); non US
nativity (k = 2); non-white race or Hispanic ethnicity
(k = 18); LEP (k = 4); and low-literacy (k = 3), Fig. 2.
One-third of trials addressing decision making in BCa
prevention or treatment targeted a socially disadvan-
taged group, but none of the three on BCa prevention in
high risk groups included disadvantaged groups. One of
five studies about BRCA genetic testing included repre-
sentation of non-White patients (Black women). All six
studies about CRC screening included at least one disad-
vantaged group; the sole study on CRC genetic testing
did not. Most trials addressing PCa screening included
at least one disadvantaged group, and one of these studies
addressed five disadvantaged subgroups. Two of three
PCa treatment trials included one disadvantaged group.
Attention to SDH in PtDA development
We conducted a secondary search for additional qualita-
tive and quantitative reports about the development of








Not RCT evaluating DA (k=57)
No active decision (k=1)
Not targeting patients (k=2)









Not U.S. RCTs (k=100)
Not cancer-related (k=17)
Fig. 1 Flow Diagram of Study Selection
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Table 1 Inclusion of Disadvantaged Social Groups in RCTs of Cancer-Related PtDAs, by Cancer Context (k = 39)










BCa, Genetic Testing (k = 5)
Green 2001 [38] BRCA testing Urban-South (n = 72) No NA No No No No No
Green 2004 [39] BRCA testing Urban-MW/NE/South
(n = 211)
No NA No No No No No
Lerman 1997 [40] BRCA testing Urban-South (n = 400) No NA No No Yes No No
Miller 2005 [41] BRCA testing National (n = 279) No NA No No No No No
Schwartz 2001 [42] BRCA testing Urban-South (n = 381) No NA No No No No No
BCa, High Risk Prevention (k = 3)
Fagerlin 2011 [43–45] Chemoprevention Urban-MW/West
(n = 1,197)
No NA No No No No No
Ozanne 2007 [46] Lifestyle v.
chemoprevention
v. surgery
Urban-West (n = 30) No NA No No No No No




No NA No No No No No
BCa, Treatment (k = 4)
Heller 2008 [49] Breast reconstruction Urban-South (n = 133) No NA No No No No No
Jibaja-Weiss 2011 [50] BCT v. mastectomy Urban-South (n = 76) No NA Yes No Yes Yes Yes
Marcus 2013 [51] BCT v. mastectomy National (n = 340) No NA No No Yes No No
Street 1995 [52] BCT v. mastectomy Urban-South (n = 60) Yes NA No No No No No
CRC, Screening (k = 6)
Dolan 2002 [53] FOBT/FS/ COL/ DCBE Urban-NE (n = 95) Yes Yes No No No No No
Miller 2011 [56] FOBT/FS/COL Urban-South (n = 264) Yes Yes Yes No Yes No Yes
Pignone 2000 [57] FOBT/FS Urban-South (n = 249) Yes Yes No No Yes No No
Ruffin IV 2007 [58] FOBT/FS/ COL Urban/Rural-MW
(n = 174)
No Yes No No Yes No No
Schroy 2011 [59, 60] FOBT/FS/COL/ DCBE Urban-NE (n = 825) Yes Yes Yes No Yes No No
Wolf 2000 [61] FOBT/FS Urban-NE/South
(n = 402)
Yes Yes No No No No No
CRC, Genetic Testing
(k = 1)
Manne 2010 [54, 55] MSI testing Urban-NE/South
(n = 213)
No No No No No No No
PCa Screening (k = 17)
Allen 2010 [62] PSA testing Urban-NE (n = 812) No NA No No No No No
Chan 2011 [63] PSA testing Urban-South (n = 317) Yes NA Yes Yes Yes Yes Noa
Frosch 2003 [64] PSA testing Urban-West (n = 226) No NA No No No No No
Frosch 2008 [65] PSA testing Urban-West (n = 611) No NA No No No No No
Krist 2007 [66] PSA testing Urban-South (n = 497) No NA No No No No No
Lepore 2012 [67] PSA testing Urban-NE (n = 490) Yes NA No Yes Yes No No
Myers 2005 [68] PSA testing Urban-NE (n = 242) Yes NA No No Yes No No
Myers 2011 [69] PSA testing Urban-NE (n = 313) No NA No No Yes No No
Partin 2004 [70] PSA testing MW (n = 893) Yes NA No No No No No
Rubel 2010 [71] PSA testing Urban-MW/NE/ South/
West (n = 200)
No NA No No No No No
Schapira 2000 [72] PSA testing Urban-MW (n = 257) No NA No No No No Nob
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social disadvantage in the development of the PtDAs
evaluated in 17 RCTs. This evidence (k = 12) plus the ar-
ticles reporting the results of the included RCTs are ref-
erenced in Table 2. Nearly all of the developmental work
used theoretical models to guide PtDA development,
most frequently the Ottawa Decision Support Framework
(ODSF). Several studies employed two or more PtDA
formats and/or delivery modes, including coaching or
counseling sessions, or utilized non-physician members of
the health care team to deliver or assist with delivery
of the PtDA. Racial/ethnic minorities and individuals
with limited education and/or low health literacy were
the subgroups most frequently targeted in PtDA
development.
Table 1 Inclusion of Disadvantaged Social Groups in RCTs of Cancer-Related PtDAs, by Cancer Context (k = 39) (Continued)
Sheridan 2012 [73] PSA testing Urban-South (n = 128) No NA No No Yes No No
Taylor 2013 [74] PSA testing/DRE Urban-South
(n = 1,893)
No NA No No Yes No No
Volk 1999 [75, 76] PSA testing Urban-South (n = 158) Yes NA No No Yes Yes No
Volk 2008 [77] PSA testing Urban-South (n = 450) No NA Yes No Yes No Yes
Williams 2013 [78] PSA testing Urban-South (n = 543) No NA Yes No Yes No No
Wolf 1996 [79] PSA testing Urban/Rural-NE/South
(n = 205)
Yes NA Yes No Yes No No
PCa Treatment (k = 3)
Barry 1997 [80] Active surveillance v.
prostatectomy v.
medication
Urban-West (n = 227) No NA No No No No No





No NA No No No Yes No
Marcus 2013 [51] Active surveillance v.
prostatectomy v.
radiation
National (n = 208) No NA No No Yes No No
Abbreviations: US, United States, HS high school diploma, GED general education development certificate, NA not applicable, BCa breast cancer, BRCA1/BRCA2
breast cancer genes 1 and 2, MW Midwest, NE northeast, BCT, breast-conserving therapy (lumpectomy followed by radiation), CRC colorectal cancer, FOBT fecal
occult blood testing, FS flexible sigmoidoscopy, COL colonoscopy, DCBE double contrast barium enema, PSA prostate-specific antigen, DRE digital rectal exam, PCa
prostate cancer
aDid not directly assess health literacy, but argued for low literacy levels of the participants in discussion section of paper










HS/GED or less Female Uninsured or
Medicaid













Fig. 2 Frequency of Disadvantaged Subgroups Included in Randomized Trials of Cancer-Related Patient Decision Aids (k = 39 studies). Study samples
met (Yes) or did not meet or did not report (No) criteria for being inclusive of specified subgroup, or criterion was not applicable (NA) to the cancer
context (e.g., gender specific studies)
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Content developed by research team,
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acceptability, demand tests conducted
in subgroups [108]; adapted to SPN
language [108]
A priori focus on multi-ethnic,


















LOW-LIT Content guided by formative research
with patients and developed by NCI,
literacy, patient education experts with
7th grade readability target; usability,
acceptability, demand tests conducted;
reviewed for cultural appropriateness





























Content based on educational video
[57] that was guided by subgroup
interviews;[109, 110] navigation
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FEM, BLK Content and usability testing guided
by subgroup FGs and interviews;
race-, gender- and insurance-related
issues, potential differences were
explored [111].














Content guided by expert opinion,
subgroup FGs and assessed out-of-
pocket cost concerns, cultural sensitivity
issues; usability tests conducted in
subgroups


























ODSF Script, slides + video










Content guided by key informants,
FGs; concept mapping conducted
with men/spouses; adapted to SPN
language















Content guided by expert opinion;
feedback from men in target subgroups
(including picture selection); cognitive
interviews [112]
A priori focus on black and





no PCa or BPH
history
PHM, AHP Booklet + decision
counseling session





Content field-tested by literacy expert
in face-to-face interviews with subgroup
[113]; decision counseling protocol
pilot tested in primary care practices
in target community [113]




no PCa or BPH
history
PHM, AHP Booklet + decision
counseling session











NR Video (12 min) +
coaching session
(8 min)
By patient at primary
care clinic (with
research assistance)
NONWHT Content pre-tested in FGs, cognitive







tool + booklet (~34 min)
By patients at home LOW-LIT,
BLK
Content guided by expert opinion, key
informants, subgroup FGs [114, 115];
adapted to 8th grade readability by
plain language expert; usability,
acceptability, demand tests conducted
in subgroups with limited computer/






NR Videotape (~20 min) +
brochure
By patient at PC
clinic
NR NR Stratified analysis by race (found


















Stratified analysis by literacy; a
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Content by expert opinion, key informants,
subgroup FGs [114, 115]; adapted to
8th grade readability by plain language
expert; usability tests conducted in
subgroups [114]
Stratified sub-analyses by race,













Content developed by physician











ODSF Patient at home
or oncology clinic
BLK Efficacy evaluation discussed


















Table 2 Strategies used to develop, evaluate cancer-related PtDAs for disadvantaged social groups (k = 20) (Continued)
Interactive web-based
program (~46 min) +
usual patient education
Content tailored by race via subgroup
FGs, interviews [117, 118]; feasibility,
acceptability tests conducted













program (>60 min) +
NCI print materials




Content guided by formative research
with patients and developed by NCI,
literacy/patient education experts with
7th grade readability target; usability,
acceptability, demand tests conducted;
reviewed for cultural appropriateness
[51]; features of development sample
NR [119]
NR
DM decision-making, BCa breast cancer, ODSF Ottawa Decision Support Framework, EDAM edutainment decision aid model, IDM informed decision-making, LIT low literacy, UNINS uninsured, BLK black, HSP Hispanic,
SPN Spanish language, DCS decisional conflict scale, SDM shared decision-making, NCI National Cancer Institute, NR not reported, CRCS colorectal cancer screening, REALM Rapid Estimate of Adult Literacy in Medicine,


















Development strategies included focus groups and/or
key informant interviews, cognitive interviews or ques-
tionnaires to guide content modification, concept map-
ping, and expert assessments of plain language readability
and/or cultural appropriateness. Several PtDAs featured
characters and/or narrators similar to the race/ethnicity or
social status of target subgroups. Two studies adapted the
PtDA to the users’ preferred language (Spanish). The
development process for several of the PtDAs employed
usability and/or feasibility testing, such as acceptability or
comprehensibility assessments, to explore and modify de-
sign features (e.g., language, narration, video, animation,
touch screen formats) that would make the material more
accessible for participants with limited health literacy, nu-
meracy or computer/internet skills [50, 51, 56, 58–60, 73,
74, 77, 78, 81–83]. As part of the development process,
several studies conducted activities associated with track-
ing estimated and/or actual use of the PtDA (demand test-
ing). The average time patients spent using the PtDAs
ranged from 10 to 207 min.
Attention to SDH in PtDA evaluation
We identified 14 studies with clear evidence of attention
to social disadvantage in evaluating the PtDA, according
to our stated criteria (Table 2). Most were included
based on the authors’ a priori objectives to evaluate the
effectiveness of PtDAs in specific populations (e.g., Black
men, Hispanic men, low-literacy populations), but we
also found articles that stratified analyses by or discussed
low versus high education/income, low versus adequate
literacy or race. Three studies also utilized a low-literacy
version of O’Connor’s Decisional Conflict Scale (DCS) to
reduce measurement error in limited literacy popula-
tions. Although several studies classified participants as
“low-literacy”, only one study measured literacy using
standard criteria (the Rapid Estimate of Adult Literacy
in Medicine, REALM).
Discussion
This review assessed the extent to which disadvantaged
subgroups have been included in US RCTs of cancer-
related PtDAs and summarized the strategies employed
in developing and evaluating PtDAs that address one or
more SDH. Our findings revealed that nearly 60 % of
studies were inclusive of disadvantaged participants
based on at least one criterion associated with health in-
equities [36], most frequently gender, race/ethnicity (re-
quired reporting statistics for research projects funded
by the US government), and education. Inclusion of sub-
groups disadvantaged by their insurance status, LEP,
low-literacy or non US-nativity was far less common.
The processes used to develop the PtDAs, as well as the
features of the tools that promoted or hindered decision
making in disadvantaged subgroups, were not well-
described in most studies. Our purpose was to glean key
lessons from those studies in which SDH were promin-
ent in the development or evaluation of cancer-related
PtDAs and to highlight the need for more attention to
the comprehensive range of social factors that may influ-
ence decision making among disadvantaged patients.
Below, we outline our observations and present oppor-
tunities for future research.
Inclusion of disadvantaged subgroups
Although diversity in the US is represented in a majority
of the studies reviewed, disadvantaged subgroups were
not included in some PtDA trials in numbers propor-
tional to their burden of disease for the decision making
contexts being targeted. A key example is our finding
that disadvantaged subgroups were not included in most
studies that focused on BRCA genetic testing or BCa
prevention in high risk populations. These represent im-
portant targets for PtDA studies given current research
that demonstrates significant disparities experienced by
Black and Hispanic women in awareness and use of
BRCA testing/genetic counseling [84–87]. Another im-
portant example is our finding that few cancer treatment
trials were inclusive of Black men and women, despite
their disproportionately high rates of incidence and mor-
tality for PCa or mortality for BCa, respectively [4].
These findings stimulate important questions about
how to establish an inventory of PtDAs that is most rele-
vant to disadvantaged social groups and their clinicians.
For example, we identified no PtDAs evaluated in US
RCTs that addressed the decision to give the hotly de-
bated human papillomavirus (HPV) vaccination [88, 89]
to adolescents and young women to prevent cervical
cancer. Cervical cancer morbidity and mortality rates are
highest among Hispanic, Black, American Indian and
Alaskan Native women in the US [4], while disparities in
awareness of and knowledge about HPV persist among
these populations [90]. Lung cancer morbidity and mor-
tality are highest among Black men in the US [4], and
lung cancer screening, in combination with smoking
cessation interventions, is now recommended for high
risk populations [91]. PtDAs to support prevention and
screening decisions for these conditions may be useful
to disadvantaged populations. PtDAs for cancer surveil-
lance among disadvantaged populations is also an im-
portant but understudied area. One study of Hispanic
and immigrant men found that not all patients fully rec-
ognized that watchful waiting, or opting not to be
screened, can also be responsible choices related to PCa
[63]. Other racial/ethnic differences in treatments dis-
cussed, preferred and received for localized PCa (sur-
gery, radiation therapy, and active surveillance) have also
been reported [92].
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Attention to SDH in PtDA development and evaluation
Education and health literacy
Education and health literacy were among the most widely
addressed disadvantages in the studies reviewed. Most
studies that focused on addressing limited education in
PtDA development targeted 7th to 8th grade readability as
the threshold for ease-of-use. The studies that identified
low-literacy patients as an intended audience for the PtDA
did not consistently report how this construct was defined
and/or measured. Focus group and individual interviews
were frequently used to determine whether the PtDAs
were accessible to limited education/low literacy patients.
Myers et al., for example, engaged a literacy expert
from a community-based health promotion organization
in Philadelphia to facilitate this process. The expert con-
ducted face-to-face interviews to ascertain whether Black
men recognized the purpose of a PCa screening informa-
tion booklet and understood its related language, terms
and concepts [68]. Through this process, the authors
learned that the medical terms should be simplified and
more pictures should be included. They found that an in-
creased emphasis on the issue of PCa screening as a deci-
sion to be made in partnership with a physician was also
needed – many men thought the purpose of the PtDA
was to promote PCa screening rather than to support deci-
sion making.
Several studies found that the acceptability and de-
mand for PtDAs varied between advantaged and disad-
vantaged subgroups based on PtDA format and other
design attributes. Volk et al. found that low compared to
high literacy users were willing to spend more time
viewing the PtDA [77]. Marcus et al. [51] and Taylor et
al. [74] found that participants were more likely to use
print-based versus web-based PtDAs (web-based PtDA
use was highest among White participants who reported
frequent internet use overall) [74]. Other studies ac-
knowledged that disadvantaged patients needed more
help utilizing PtDAs and facilitated delivery of the inter-
vention using non-physician members of the healthcare
team. Like the use of patient navigators to provide psy-
chosocial and logistical support for disadvantaged cancer
patients [93, 94], the use of health coaches to guide deci-
sion making [95] for disadvantaged populations may also
be needed. Appropriate consideration should be given to
both PtDA design and the other factors that may influ-
ence disadvantaged participants’ exposure to the inter-
vention. By engaging patients early in the development
process, the most appropriate PtDA formats and delivery
strategies can be identified.
The influence of PtDAs on facilitating SDM via im-
proved patient-provider communication, or even pa-
tients’ interest in participating in SDM, was discussed
rarely in identified studies. By definition, being health lit-
erate includes being able to act on health information
[96]. Several factors may influence whether patients en-
gage in SDM with their physicians (some are highlighted
below as part of our discussion regarding social norms
and attitudes). Although LEP, the use of translators in
explaining treatment options, and the lack of available
educational materials in a patient’s preferred language,
for example, are factors known to influence patients’ re-
liance on physician recommendations over more active
participation in decision making [29], PtDAs designed
for disadvantaged populations may play a role in im-
proving these aspects of patient-provider interactions.
More information is needed to better understand this
issue, particularly in light of a recent systematic review
finding that SDM interventions were more beneficial to
disadvantaged, compared to advantaged subgroups [97].
Another notable finding is the limited consideration of
numeracy in relation to health literacy. Two studies de-
scribed addressing numeracy as part of the PtDA devel-
opment process [59, 83]; one study measured and
reported participants’ baseline numeracy skills [74]. As
reported in a recent study [98], numeracy and health lit-
eracy have largely been treated as separate concepts in
the literature despite indications that PtDAs designed for
patients with different levels of health literacy may not sup-
port the needs of patients with disparate numeracy skills.
This is another important area for future research.
Race, ethnicity and related social norms and attitudes
Matching the race/ethnicity of the actors/models to that
of the intended audience is a commonly used strategy in
tailoring PtDAs for disadvantaged social groups. Jibaja-
Weiss et al. produced six versions of PtDA soap opera
segments so that users were able to receive information
about BCa treatment from female characters similar to
them in race/ethnicity, preferred language and age [50].
Volk and colleagues employed a multiethnic, blue-collar
cast and tailored the main character to the viewer
through a series of questions completed upon entering
the program [77]. The program included a values clarifi-
cation, social-matching exercise that asked the viewer to
“pick who is most like you” with regard to his feelings
about PCa screening. The strategy of promoting racial/
ethnic concordance to improve processes of care and
outcomes for minorities has been extensively studied,
with mixed results [99, 100]. The underlying assumption
is that people are able to better identify with others who
look like them or share similar language or culture. In
turn, this may improve their interactions (e.g., greater
satisfaction, trust, willingness to ask questions on the
part of patients; less uncertainty, bias, stereotyping on
the part of providers; better patient-provider communi-
cation overall). However, the influence of patient-
provider race-concordance on health care interactions
varies within and across race/ethnicity based on related
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SDH (e.g., income, citizenship status, language) [99–101].
These differences may be present in other norms and atti-
tudes related to race/ethnicity and culture (e.g. attitudes
about surgery; opinions of spouse, family and friends; con-
cerns about body image) [102]. Reflecting the racial/ethnic
diversity of target audiences in PtDAs is most certainly an
important patient engagement strategy. However, it is also
important to recognize that heterogeneity exists within ra-
cial/ethnic groups. More research is needed to better
understand whether PtDAs can help to improve decisional
outcomes that may be influenced by race/ethnicity and re-
lated social norms and attitudes.
Economic instability
Although few studies indicated that patients were asked
about economic issues during PtDA development, the
need to disentangle the various ways in which economic
instability may influence patient decision making is an im-
portant area for future research. As noted, Jibaja-Weiss et
al. [50] found that PtDA exposure was associated with in-
creased uptake of mastectomy, rather than breast conserv-
ing therapy, among low-literacy Black and Hispanic
women with early stage BCa. This finding differed from
published studies linking PtDAs with the choice to
undergo more conservative surgical options [20, 103]. The
reason for this difference remains unclear, but other stud-
ies of low income women in the US suggest that economic
factors (e.g. uninsured or Medicaid status, insurance co-
payments, out-of-pocket expenses, concerns about missed
work) influence their treatment choices [29, 104, 105].
Other SDH
Multiple factors affect the health and health care re-
ceived by disadvantaged populations, including many
SDH that were not addressed in this research. In some
decision contexts, for example, it may be important to
use PtDAs to help patients consider how attributes of
their neighborhoods and built environments (e.g., hous-
ing, transportation, public safety, other public services,
environmental noise and pollutants) figure into their de-
cision making. We do not mean to suggest that all SDH
can be practically addressed in every PtDA for disadvan-
taged patients. However, if the purpose of PtDAs is to
support high quality SDM in the cancer care continuum,
we believe that addressing only education and/or health
literacy when developing tools for patients who face
multiple social disadvantages falls short of that goal.
Limitations and strengths
This review has several potential limitations. First, despite
our efforts to identify all US RCTs of cancer-related PtDAs,
it is possible that our search missed relevant RCTs that fit
our inclusion criteria. We attempted to minimize this pos-
sibility by comparing our list of eligible studies with those
in recently published systematic reviews of PtDAs using
similar search and eligibility criteria [20, 106, 107]. By lim-
iting our review to RCTs, we may have missed studies that
were more inclusive of disadvantaged subgroups or that
employed PtDA development and evaluation strategies
other than those described in the articles identified for this
review. Yet, given the large number of RCTs of cancer-
related PtDAs that have been conducted [20], and given
the importance of the Cochrane review, limiting this re-
view to the Cochrane criteria of RCTs seems appropriate.
We did include citing and cited publications related to the
RCTs that cast a larger net for information on PtDA devel-
opment. We did not, however, contact the study authors
for additional information, which may have potentially
caused us to miss relevant information not consistently re-
ported. We attempted to address this problem by focusing
our data collection on socioeconomic and cultural con-
structs most widely and consistently reported in the litera-
ture. We acknowledge that other constructs related to
social disadvantage, such as social capital, place of resi-
dence, physical and mental disability, sexual orientation or
religion, are important characteristics that should be more
consistently reported and evaluated in future PtDA re-
search. We were unable to identify a cancer-related PtDA
trial that addressed social disadvantages related to these
characteristics. Limitations present in all systematic re-
views, including publication bias and potential researcher
bias in establishing study inclusion criteria, may also have
been present in this study.
Conclusions
The number of cancer-related PtDAs will continue to
proliferate in the coming years as such tools are advo-
cated as a strategy to facilitate patient engagement in
SDM. While it may be tempting to evaluate or utilize
PtDAs developed without attention to SDH and argue
that the tools are effective based on improvements in
knowledge measured broadly or other decisional outcomes,
we believe such an approach misses many important con-
siderations in providing decision support that may ultim-
ately undermine quality decision-making processes. This
review addresses a gap in the literature by summarizing the
extent to which cancer-related PtDAs have been used by
disadvantaged patients in the US and by highlighting the
strategies and lessons learned in the development and
evaluation of the handful of PtDAs specifically tailored for
disadvantaged social groups. Such information may be used
to guide clinicians as they attempt to identify among a large
and expanding inventory of available PtDAs those tools that
that were designed to support the decision making needs of
their socially disadvantaged patients. It may also be used to
inform the development of new or complementary inter-
ventions to support high quality SDM processes among dis-
advantaged populations.
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